4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates
Objective: This study investigated the antidyskinetic activity of 4-chlorokynurenine (AV-101) in parkinsonian monkeys with L-Dopa-induced dyskinesias. Background: The common treatment for Parkinson’s disease (PD) is L-Dopa…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…The Subthalamic Fasciculus and Connectivity Profiling of Stimulation-induced Dyskinesia following Pallidal DBS in Parkinson’s Disease
Objective: To identify anatomical regions related to stimulation-induced dyskinesia (SID) following pallidal deep brain stimulation (DBS) in Parkinson’s disease (PD) and to analyze structural and…The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease: a pilot study
Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Gpi Deep Brain Stimulation After Many Years of Subthalamic Nucleus Stimulation: Case Report
Objective: Management of motor complications after subthalamic nucleus (STN) deep brain stimulation (DBS) with globus pallidus interna (Gpi) stimulation. Background: Deep brain stimulation is an…Is early-onset of levodopa-induced dyskinesia a predictor of GBA mutation? A next-generation sequencing study of young-onset Parkinson’s disease patients in Thailand
Objective: To examine the prevalence of genetic causes in young-onset Parkinson’s disease (YOPD) patients with levodopa-induced dyskinesia (LID) in Thailand using a next-generation sequencing (NGS)…Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Persistent head dyskinesias following STN DBS in Parkinson’s disease resolve using directionality
Objective: To control subthalamic nucleus deep brain stimulation (STN DBS) induced dyskinesias in Parkinson's disease (PD) using directionality. Background: Levodopa-induced dyskinesias (LID) frequently occur in…Intrinsic brain functional connectivity predicts treatment-related motor complications in drug-naive Parkinson’s disease patients
Objective: Using resting-state functional MRI, we investigated intrinsic brain networks connectivity at baseline in a cohort of drug-naïve Parkinson’s disease (PD) patients which successively developed treatment-related…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 49
- Next Page »